Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALXN2040 + rosuvastatin
- Development stage
- Unknown
- Lead developer
- Alexion Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ALXN2040 + rosuvastatin is a combination of ALXN2040 (danicopan), a small molecule oral inhibitor of complement factor D, and rosuvastatin, a statin used for lowering cholesterol. This combination has been investigated to assess potential drug-drug interactions, particularly the effect of ALXN2040 on the pharmacokinetics of rosuvastatin. ALXN2040 (danicopan) is developed primarily by Alexion Pharmaceuticals as an alternative complement pathway inhibitor, while rosuvastatin acts as an HMG-CoA reductase inhibitor reducing cholesterol biosynthesis. Their coadministration is notable for increased rosuvastatin exposure due to ALXN2040's inhibition of the breast cancer resistance protein (BCRP), which can elevate statin plasma concentrations[1][5][6].
- Brand names
- VOYDEYA
- Other names
- ALXN2040 + rosuvastatin
02
Targets
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)CFD (Complement Factor D)
Beyond the preview
Go deeper on ALXN2040 + rosuvastatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ALXN2040 + rosuvastatin.